What significant regulatory action occurred in 2000 regarding ritonavir?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Prepare for the Drug Action 2 Exam. Focus on multiple-choice questions, learn through interactive quizzes, and understand core drug mechanisms with explanations. Dive deep into pharmacokinetics and pharmacodynamics to ace your test!

Multiple Choice

What significant regulatory action occurred in 2000 regarding ritonavir?

Explanation:
In 2000, the FDA approved a fixed‑dose combination HIV drug, lopinavir/ritonavir (marketed as Kaletra). Ritonavir was included at a boosting dose to inhibit the liver enzyme CYP3A4, which raises lopinavir levels and enhances the overall antiviral effect. This created an effective boosted protease inhibitor regimen and helped simplify therapy by combining two drugs into one pill. It wasn’t a standalone ritonavir approval, nor a withdrawal or a pediatric‑only approval at that time.

In 2000, the FDA approved a fixed‑dose combination HIV drug, lopinavir/ritonavir (marketed as Kaletra). Ritonavir was included at a boosting dose to inhibit the liver enzyme CYP3A4, which raises lopinavir levels and enhances the overall antiviral effect. This created an effective boosted protease inhibitor regimen and helped simplify therapy by combining two drugs into one pill. It wasn’t a standalone ritonavir approval, nor a withdrawal or a pediatric‑only approval at that time.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy